| Literature DB >> 35267796 |
Ssu-Meng Huang1, Shih-Ming Liu1, Chia-Ling Ko1, Wen-Cheng Chen1,2,3.
Abstract
Hydroxyapatite (HA), especially in the form of HA nanoparticles (HANPs), has excellent bioactivity, biodegradability, and osteoconductivity and therefore has been widely used as a template or additives for drug delivery in clinical applications, such as dentistry and orthopedic repair. Due to the atomically anisotropic distribution on the preferred growth of HA crystals, especially the nanoscale rod-/whisker-like morphology, HA can generally be a good candidate for carrying a variety of substances. HA is biocompatible and suitable for medical applications, but most drugs carried by HANPs have an initial burst release. In the adsorption mechanism of HA as a carrier, specific surface area, pore size, and porosity are important factors that mainly affect the adsorption and release amounts. At present, many studies have developed HA as a drug carrier with targeted effect, porous structure, and high porosity. This review mainly discusses the influence of HA structures as a carrier on the adsorption and release of active molecules. It then focuses on the benefits and effects of different types of polymer-HA composites to re-examine the proteins/drugs carry and release behavior and related potential clinical applications. This literature survey can be divided into three main parts: 1. interaction and adsorption mechanism of HA and drugs; 2. advantages and application fields of HA/organic composites; 3. loading and drug release behavior of multifunctional HA composites in different environments. This work also presents the latest development and future prospects of HA as a drug carrier.Entities:
Keywords: carriers; composites; drug release; hydroxyapatite; nanoparticles; protein; scaffold; template; tissue engineering
Year: 2022 PMID: 35267796 PMCID: PMC8912323 DOI: 10.3390/polym14050976
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Schematic diagram of the adsorption and attachment factor mechanism of porous HA nanorod [52].
Figure 2Schematic diagram of drug adsorption on the surface-modified HANPs. (−: negatively charged biding sites on surfaces of modified HANPs; D: active molecule of drugs.)
Related applications of different types of HANP structures as a template in carrying proteins/drugs.
| HANP Structures | Proteins/Drug | Highlights and Potential Clinical Applications | Ref. |
|---|---|---|---|
| Solid (non-porous) hydroxyapatite nanoparticles (HANPs) | Pepsin A | Comparing the effects of different types of HA modified with cetyl pyridine chloride on the interaction with pepsin A, HANPs have higher enzymatic activity (18.45%) than microscale. HANPs with surface modification can improve their use in biomedical applications potential. | [ |
| Mesoporous hydroxyapatite nanoparticles (M-HANPs) | Bovine serum albumin (BSA) | The adsorption capacity of M-HANPs in acidic environment (pH 4.7) was higher than that of micro-HA particles. In alkaline environments (pH 8.4), they have smaller bursts and flatter release profiles, which can be used for targeted drug delivery and bone therapy. | [ |
| Mesoporous hydroxyapatite rod-like nanocrystals | Fetuin from serum protein | Fetuin has the ability to inhibit the growth of M-HA nanocrystals to form dumbbell shaped, mesoporous structure, and large surface area. M-HAs of rod-like crystal size (235–515 nm) with inner mesopores (21–31 nm) can load more drugs and sustained-release drugs, which is beneficial to the field of drug delivery and sustained-release as drug delivery vehicles. | [ |
| Hollow mesoporous hydroxyapatite nanoparticles | Doxorubicin (DOX) | The hollow mesoporous structure of M-HANPs has high biocompatibility and good drug loading capacity, the drug loading rate is increased from 17.9% to 93.7%, and has excellent drug nanocarrier performance as carriers of large pharmaceutics. | [ |
| Solid and mesoporous hydroxyapatite nanoparticles | Ciprofloxacin | Compared with solid HANPs, M-HANPs have higher specific surface area and high drug loading, and have greater application potential in the field of drug delivery. Therefore, M-HANPs can potentially be used in smart drug delivery systems. | [ |
| Functionalization of hydroxyapatite nanoparticles | curcumin nanoparticles | Carboxylic acid surface modification of HANPs can enhance the adsorption of curcumin and improve its drug availability. Curcumin-modified HANPs have better anticancer activity and have good potential in the field of medical regeneration. | [ |
Figure 3Fiber-based membranes were prepared by electrospinning simulated polymer composite HANPs.
Figure 4Schematic diagram of 3D printing to prepare polymer composite HANP scaffolds.
Figure 5Schematic diagram of the preparation of porous scaffolds of polymers composite HANPs prepared by freeze-drying.
Figure 6Appearances of (a) electrospun film; (b) freeze-dried scaffold; (c) freeze-dried beads (d) microspheres, and (e) electrospray nanospheres.
Characteristics and possible clinical applications of different types of polymer-HA composites.
| Biomolecules with Different Types of Appearance | Drug | Highlights and Potential Clinical Applications | Ref. |
|---|---|---|---|
| TCH/HANPs/CG core–shell nanofibers | Tetracycline hydrochloride (TCH) | The composite nanofibers have long-lasting antibacterial function, good biocompatibility, and high mechanical strength, and are suitable for wound dressings and drug delivery systems. | [ |
| HANPs/PLGA microspheres | − | The diameter of the composite microspheres is about 250 μm. When the content of HANPs was 20% and 40%, respectively, it could promote the mineralization and osteogenic differentiation of MC3T3-E1 cells, and had good clinical application potential in bone tissue engineering and bone implantation. | [ |
| HANPs-containing alginate–gelatin composite films | Tetracycline hydrochloride (TCH) | The addition of HANPs will make the surface of the composite film rougher and effectively improve the thermal stability. In addition, it can reduce the initial burst release of the drug. The polymer-HA composite film can be used not only for biomedical applications, but also for food packaging. | [ |
| Polycaprolactone/ polyethylene oxide/ hydroxyapatite 3D scaffolds | Vancomycin (VCM) | The composite scaffold with HA content of 65% had the best wettability and mechanical properties, but adding too much HA would affect the mechanical properties of the polymer-HA composite. The drug release showed an initial burst, and the 3D scaffold with antibacterial activity was suitable for bone tissue engineering applications. | [ |
| A chitosan (CS)-coated polytrimethylene carbonate (PTMC)/polylactic acid (PLLA)/oleic acid-modified hydroxyapatite (OA-HA)/vancomycin hydrochloride (VH) microsphere scaffold | vancomycin hydrochloride (VH) | Two active molecules, OA-HA and VH, can be released through the pores. In addition to facilitating osteoblast adhesion, CS coating can also control the release behavior of the OA-HA to stimulate the proliferation of osteoblasts, which is expected to be used in bone tissue engineering. | [ |